Form 4 for CRL Charles River Laboratories
Accepted 2024-02-05 00:00:00 ET · period of report 2024-02-01 · accession 0001127602-24-003484 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-05 | 2024-02-01 | CRL | Kemps-Polanco Reshema | Dir | A - Grant | $0.00 | +170 | 170 | New | $0 |
| D | 2024-02-05 | 2024-02-01 | CRL | Kemps-Polanco Reshema | Dir | A - Grant | $219.54 | +399 | 399 | New | +$87.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-01 | A | A | 170 | $0.00 | 170 | D | — | — | (F1) Consists of 170 unvested restricted stock units that vest on 5/7/2024. |
| 2 | Derivative | Stock Options (Right to Buy) | 2024-02-01 | A | A | 399 | $219.54 | 399 | D | $219.54 · 2024-05-07 to 2034-02-01 | 399 Common Stock | (F2) The stock options become exercisable 5/7/2024. |